Mesenchymal stem cell therapy - Pandorum International
Latest Information Update: 28 Apr 2026
At a glance
- Originator Pandorum International
- Developer Medical University of South Carolina; Pandorum International
- Class Mesenchymal stem cell therapies; Skin disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Adult respiratory distress syndrome
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in USA (IV, Infusion)
- 03 Oct 2024 Medical University of South Carolina wihdrawns phase I trial in Adult respiratory distress syndrome in USA prior to enrollment (IV) (NCT05286255)
- 31 Mar 2022 Institutional Review Board (IRB) approves SAMPSON 1 phase I trial in COVID-19 pneumonia